Drug Profile
SCIB 1
Alternative Names: Cancer vaccine - Scancell; ImmunoBody melanoma vaccine - Scancell; Melanoma vaccine TRP2 gp100 - Scancell; SCIB-1Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Scancell
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Malignant melanoma
Highest Development Phases
- Phase II Malignant melanoma
Most Recent Events
- 26 Mar 2024 Scancell plans a phase II/III adaptive registrational trial for Malignant melanoma (Inoperable/Unresectable)
- 30 Jan 2024 Efficacy data from the phase II SCOPE trial in Malignant melanoma released by Scancell
- 28 Sep 2023 Efficacy data from the phase II SCOPE trial in Malignant melanoma released by Scancell